Watson Bio’s live attenuated varicella vaccine clinical trial approved
February 12, 2026
Source: drugdu
34
Beijing Business Daily , February 10th - Watson BiotechnologyThe company announced that its varicella attenuated live vaccine, jointly developed and applied for clinical trials by the company and its subsidiaries Yunnan Vaccine Laboratory Co., Ltd., Beijing Watson Innovation Biotechnology Co., Ltd., and Yuxi Watson Biotechnology Co., Ltd., recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, agreeing to conduct clinical trials for the prevention of varicella.
The announcement indicates that the vaccine is a live attenuated vaccine produced by inoculating human diploid cells with an attenuated strain of varicella-zoster virus and then freeze-drying it. After vaccination, it stimulates the body to produce immunity against the varicella-zoster virus, thus preventing chickenpox. Currently, six companies in China have received marketing authorization for their live attenuated varicella vaccines.
https://finance.eastmoney.com/a/202602103646820558.html
Copyright©2026 Ddu. All rights reserved.
Read more on
- The first patient in the Phase IB/II trial of Verizon’s triple-negative breast cancer was successfully treated. February 12, 2026
- The first subject has been dosed in the Phase II clinical trial of its innovative small nucleic acid drug EDP167. February 12, 2026
- Novo Nordisk’s oral weight-loss drug advertisement has been flagged by the FDA for allegedly misleading advertising. February 12, 2026
- Visipine®, the first and only oral S1P receptor modulator for ulcerative colitis in my country, has been approved, ushering in a new era of “deep healing”. February 12, 2026
- Multi-dimensional Breakthroughs in Policy, Rules, and Pricing February 12, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
